<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03142334</url>
  </required_header>
  <id_info>
    <org_study_id>3475-564</org_study_id>
    <secondary_id>2016-004351-75</secondary_id>
    <secondary_id>173704</secondary_id>
    <secondary_id>MK-3475-564</secondary_id>
    <nct_id>NCT03142334</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)</brief_title>
  <official_title>A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475)
      in the adjuvant treatment of adult participants who have undergone nephrectomy and have
      intermediate-high risk, high risk, or M1 no evidence of disease (M1 NED) renal cell carcinoma
      (RCC) with clear cell component.

      The primary study hypothesis is that pembrolizumab is superior to placebo with respect to
      Disease-free Survival (DFS) as assessed by the Investigator in male and female participants
      with intermediate-high risk, high risk and M1 NED RCC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be assigned to receive study treatment until disease recurrence,
      unacceptable adverse events (AEs), intercurrent illness that prevents further administration
      of treatment, Investigator's decision to withdraw the participant, noncompliance with study
      treatment or procedural requirements, administrative reasons requiring cessation of
      treatment, or until the participant has received 17 cycles of study treatment (approximately
      1 year). Each cycle is 3 weeks long.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 9, 2017</start_date>
  <completion_date type="Anticipated">November 12, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 12, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free Survival (DFS) as Assessed by the Investigator</measure>
    <time_frame>Up to approximately 72 months</time_frame>
    <description>DFS, as assessed by the investigator, is defined as the time from randomization to the first documented local recurrence, distant metastasis, secondary systemic malignancy, or death due to any cause, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 72 months</time_frame>
    <description>OS is defined as the time from randomization to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Nonserious AEs: Up to 30 days after last dose of study treatment (Up to approximately 13 months); Serious AEs: Up to 90 days after last dose of study treatment (Up to approximately 15 months)</time_frame>
    <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study treatment, whether or not considered related to the use of study treatment. Participants are monitored for the occurrence of nonserious AEs for up to 30 days after last dose of study treatment and of serious AEs for up to 90 days after last dose of study treatment. The number of participants who experience an AE will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Treatment Discontinuations Due to an AE</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study treatment, whether or not considered related to the use of study treatment. The number of participants who discontinue study treatment due to an AE will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First Local Disease Recurrence-specific Survival (DRSS1) as Assessed by the Investigator</measure>
    <time_frame>Up to approximately 72 months</time_frame>
    <description>DRSS1 is defined as the time from randomization to the first documented local recurrence of RCC as assessed by the investigator. For DRSS1, only local recurrence is counted as an event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First Local Recurrence with Visceral Lesion or Distant Metastasis with Visceral Lesion or Secondary Systemic Malignancy with Visceral Lesion (DRSS2) as Assessed by the Investigator</measure>
    <time_frame>Up to approximately 72 months</time_frame>
    <description>DRSS2 is defined as the time from randomization to the first documented local recurrence with visceral lesion or distant metastasis with visceral lesion or secondary systemic malignancy with visceral lesion, whichever occurs first, as assessed by the investigator. For DRSS2, only disease recurrence with visceral lesion is counted as an event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DFS According to Participant Programmed Cell Death-Ligand 1 (PD-L1) Expression Status (Positive, Negative) as Assessed by the Investigator</measure>
    <time_frame>Up to approximately 72 months</time_frame>
    <description>DFS, as assessed by the investigator, is defined as the time from randomization to the first documented local recurrence, distant metastasis, secondary systemic malignancy, or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS According to Participant PD-L1 Expression Status (Positive, Negative)</measure>
    <time_frame>Up to approximately 72 months</time_frame>
    <description>OS is defined as the time from randomization to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Clearance (CL) of Pembrolizumab</measure>
    <time_frame>Cycles 1 and 2: Pre-dose and 0.5 hours (h) after end of infusion; Cycles 3, 5, 13 and 17: Pre-dose; and 30 days after study treatment discontinuation. Each cycle is 3 weeks long. (Up to approximately 13 months)</time_frame>
    <description>CL is the volume of plasma from which a substance is completely removed per unit time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution (VD) of Pembrolizumab</measure>
    <time_frame>Cycles 1 and 2: Pre-dose and 0.5 h after end of infusion; Cycles 3, 5, 13 and 17: Pre-dose; and 30 days after study treatment discontinuation. Each cycle is 3 weeks long. (Up to approximately 13 months)</time_frame>
    <description>The VD of a drug represents the degree to which a drug is distributed in body tissue rather than the plasma. VD is directly correlated with the amount of drug distributed into tissue; a higher VD indicates a greater amount of tissue distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Anti-pembrolizumab Antibodies</measure>
    <time_frame>Cycles 1, 3, 5, 13 and 17: Pre-dose; and 30 days after study treatment discontinuation. Each cycle is 3 weeks long. (Up to approximately 13 months)</time_frame>
    <description>The number of participants who develop serum anti-pembrolizumab antibodies will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) Total Score</measure>
    <time_frame>Baseline and Cycles 1, 5, 9, 13, and 17, treatment discontinuation, 30 day follow up, and annually during post-treatment follow up. Each cycle is 3 weeks long. (Up to approximately 72 months)</time_frame>
    <description>The QLQ-C30 quality of life (QOL) questionnaire contains 5 functioning scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, nausea and vomiting, and pain) and single symptom items (dyspnoea, loss of appetite, insomnia, constipation and diarrhoea) and perceived financial impact of the disease. Items are scored on a 4-point scale (1=not at all, 2=a little, 3= quite a bit, 4=very much). The QLQC30 also contains 2 global health status scales that use 7-point scale scoring (1=very poor and 7=excellent). The change from baseline in the 2-item global health status/QOL life scale (range: 2-14) will be presented, with a higher score representing a higher QOL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Cancer Therapy Kidney Symptom Index-Disease Related Symptoms (FKSI-DRS) Index Score</measure>
    <time_frame>Baseline and Cycles 1, 5, 9, 13, and 17, treatment discontinuation, 30 day follow up, and annually during post-treatment follow up. Each cycle is 3 weeks long. (Up to approximately 72 months)</time_frame>
    <description>The FKSI-DRS index consists of a 9-item questionnaire that assesses the extent of participant symptoms from kidney cancer over the previous 7 days. Responses are scored on a 5-point scale (0=Not at all to 4=Very much) and summed to generate an index symptom score. These scores can range from 0 to 36, with a higher score indicating more favorable kidney cancer symptom status.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">950</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 17 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive placebo (saline solution) via IV infusion on Day 1 of each 3-week cycle for up to 17 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <other_name>MK-3475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (saline solution)</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has histologically confirmed diagnosis of RCC with clear cell component with or
             without sarcomatoid features.

          -  Female participants of childbearing potential must be willing to use an adequate
             method of contraception, for the course of the study through 120 days after the last
             dose of study treatment.

          -  Male participants of childbearing potential must agree to use an adequate method of
             contraception, starting with the first dose of study treatment through 120 days after
             the last dose of study treatment.

          -  Has intermediate-high risk, high risk, or M1 NED RCC as defined by the following
             pathological tumor-node-metastasis and Fuhrman grading status:

               1. Intermediate-high risk RCC: pT2, Grade 4 or sarcomatoid, N0, M0; pT3, Any Grade,
                  N0, M0

               2. High risk RCC: pT4, Any Grade N0, M0; pT, Any stage, Any Grade, N+, M0

               3. M1 NED RCC participants who present not only with the primary kidney tumor but
                  also solid, isolated, soft tissue metastases that can be completely resected at
                  one of the following: the time of nephrectomy (synchronous) or, ≤1 year from
                  nephrectomy (metachronous).

          -  Has received no prior systemic therapy for advanced RCC.

          -  Has undergone a partial nephroprotective or radical complete nephrectomy (and complete
             resection of solid, isolated, soft tissue metastatic lesion(s) in M1 NED participants)
             with negative surgical margins.

          -  Must have undergone a nephrectomy and/or metastasectomy ≥28 days prior to signing
             informed consent and ≤12 weeks prior to randomization.

          -  Must be tumor-free as assessed by the Investigator and validated by either computed
             tomography (CT) or magnetic resonance imaging (MRI) scan of the brain and chest,
             abdomen, and pelvis and a bone scan ≤28 days from randomization.

          -  Must have provided adequate tissue per the following: Nephrectomy only: tissue from
             nephrectomy (required); Synchronous M1 NED: tissue from nephrectomy (required) AND,
             metastasectomy tissue (if available); Metachronous M1 NED: tissue from metastasectomy
             (required) AND, nephrectomy tissue (if available).

          -  Has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or
             1.

          -  Has adequate organ function.

        Exclusion Criteria:

          -  Has had major surgery, other than nephrectomy and/or resection of pre-existing
             metastases for M1 NED participants, within 12 weeks prior to randomization.

          -  Has received prior radiotherapy for RCC.

          -  Has pre-existing brain or bone metastatic lesions.

          -  Has residual thrombus post nephrectomy in the vena renalis or vena cava.

          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
             (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
             immunosuppressive therapy within 7 days prior the first dose of study treatment.

          -  Has an active autoimmune disease that has required systemic treatment in past 2 years
             (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive
             drugs). Replacement therapy is allowed.

          -  Has a known additional malignancy that is progressing or required active treatment ≤3
             years ago. Exceptions include early-stage cancers (carcinoma in situ or Stage 1)
             treated with curative intent, basal cell carcinoma of the skin, squamous cell
             carcinoma of the skin, in situ cervical cancer, in situ prostate cancer, or in situ
             breast cancer that has undergone potentially curative therapy.

          -  Has a history of (non-infectious) pneumonitis that required steroids or has current
             pneumonitis.

          -  Has an active infection requiring systemic therapy.

          -  Has a history of, or is currently on, dialysis.

          -  Has a known history of human immunodeficiency virus (HIV) infection.

          -  Has known active hepatitis B or hepatitis C virus infection.

          -  Has a known history of active tuberculosis (Bacillus tuberculosis).

          -  Has had a prior solid organ transplant.

          -  Has severe hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients.

          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the study, starting with the Screening visit through 120 days
             after the last dose of study treatment.

          -  Has received prior therapy with an anti-programmed cell death protein 1 (anti-PD-1),
             anti-programmed cell death-ligand 1 (anti-PD-L1), or anti-PD-L2 agent or with an agent
             directed to another co-inhibitory T-cell receptor (i.e., cytotoxic
             T-lymphocyte-associated protein 4 [CTLA-4], OX-40, CD137 [tumor necrosis factor
             receptor superfamily member 9 (TNFRSF9)]) or has previously participated in a Merck
             pembrolizumab (MK-3475) clinical trial.

          -  Has received prior anticancer therapy, monoclonal antibody, chemotherapy, or an
             investigational agent or device within 4 weeks or 5 half-lives (whichever is longer)
             before first dose of study treatment or not recovered (i.e., must be ≤ Grade 1 or at
             Baseline) from AEs due to previously administered agents.

          -  Has received a live vaccine within 30 days prior to the first dose of study treatment.

          -  Is currently participating in or has participated in a study of an investigational
             agent or has used an investigational device within 4 weeks prior to the first dose of
             study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC- HAL ( Site 8018)</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>602-277-4868</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center ( Site 0038)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>323-865-3956</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center ( Site 0028)</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>650-736-1252</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sansum Clinic Research ( Site 8014)</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>218-863-6685</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center ( Site 8010)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-863-6712</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center ( Site 0002)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>202-687-1116</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boca Raton Regional Hospital- Lynn Cancer Institute ( Site 0035)</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>561-955-5630</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwest Georgia Oncology Centers Pc ( Site 0014)</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>770-281-5156</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Specialists ( Site 8001)</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>218-863-6685</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospital and Clinics ( Site 0031)</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>319-356-1616</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weinberg Cancer Institute at Franklin Square ( Site 0046)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>443-777-7364</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Ctr. ( Site 0044)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-975-7422</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute (Boston) ( Site 0007)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-582-7334</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan ( Site 0045)</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>734-232-0753</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute ( Site 0013)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>313-576-9372</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital ( Site 0032)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>313-916-1784</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Quest Research Institute ( Site 0036)</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Fairview Southdale Medical Oncology Clinic ( Site 0041)</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>612-672-5233</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Specialist, PA ( Site 8002)</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-863-6712</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Park Nicollet Frauenshuh Cancer Center ( Site 0020)</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>952-993-1737</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Vincent Healthcare Frontier Cancer Center ( Site 0008)</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>406-238-6290</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Specialists ( Site 0012)</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>402-334-4773</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada ( Site 8013)</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center ( Site 0043)</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>505-925-0414</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center ( Site 0009)</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>718-405-8405</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care, Inc. ( Site 8008)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-863-6685</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C. ( Site 8006)</name>
      <address>
        <city>Tualatin</city>
        <state>Oregon</state>
        <zip>97062</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>218-863-6685</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Luke's University Health Network ( Site 0042)</name>
      <address>
        <city>Easton</city>
        <state>Pennsylvania</state>
        <zip>18045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>484-503-4154</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center ( Site 0010)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>215-662-4000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charleston Hematology Oncology Associates PA ( Site 8000)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>843-723-4358</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina ( Site 0033)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>843-792-2306</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Avera Cancer Institute ( Site 0023)</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>605-322-3018</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Austin Central ( Site 8003)</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>218-863-6685</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor Sammons Cancer Center/ Texas Oncology ( Site 8019)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-863-6712</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Denton South ( Site 8016)</name>
      <address>
        <city>Denton</city>
        <state>Texas</state>
        <zip>76210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-863-6712</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Memorial City ( Site 8015)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-863-6685</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UTHealth/Memorial Hermann Cancer Center ( Site 0001)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>832-325-7702</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology- Paris ( Site 8004)</name>
      <address>
        <city>Paris</city>
        <state>Texas</state>
        <zip>75460-5004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-863-6712</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CTRC at The University of Texas Health Science Center at San Antonio ( Site 0026)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>210-450-5798</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Tyler ( Site 8005)</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-863-6712</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Waco ( Site 8012)</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>218-863-6685</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates ( Site 8011)</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>218-863-6685</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Regional Cancer Partnership ( Site 0016)</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>425-297-5577</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SCCA/UW ( Site 0029)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>206-288-7476</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Care Northwest ( Site 0021)</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>509-228-1687</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates (Summit Cancer Centers) ( Site 0005)</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>509-462-2273</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties, PLLC ( Site 0034)</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>253-428-8725</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yakima Valley Memorial Hospital North Star Lodge ( Site 8017)</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Carbone Cancer Center ( Site 0019)</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>608-263-7107</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanatorio Parque ( Site 1104)</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5493416149812</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Riojano Integral ( Site 1101)</name>
      <address>
        <city>La Rioja</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+54380154271207</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico de Integracion Regional. COIR ( Site 1109)</name>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5492615736010</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de Oncologia de Rosario ( Site 1100)</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+543414218909</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanatorio Britanico S.A. ( Site 1106)</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+543414205500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Medico San Roque ( Site 1108)</name>
      <address>
        <city>Tucuman</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5493815186197</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Clinicas - Clinica Viedma ( Site 1102)</name>
      <address>
        <city>Viedma</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5492920601693</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Macquarie University Hospital ( Site 0700)</name>
      <address>
        <city>Macquarie University</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61298502766</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Adelaide Cancer Centre ( Site 0703)</name>
      <address>
        <city>Kurralta Park</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61882922240</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital ( Site 0701)</name>
      <address>
        <city>Box Hill</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61398953281</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital ( Site 0702)</name>
      <address>
        <city>Perth</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61861526531</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Nossa Senhora da Conceicao ( Site 1000)</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5551991922412</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacao Pio XII - Hospital de Cancer de Barretos ( Site 1002)</name>
      <address>
        <city>Barretos</city>
        <state>Sao Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+551733216638</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universidade de Caxias do Sul ( Site 1004)</name>
      <address>
        <city>Caxias do Sul</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5511432182026</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Bruno Born ( Site 1015)</name>
      <address>
        <city>Lajeado</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5551371475002476</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>COT Centro Oncologico do Triangulo Ltda ( Site 1014)</name>
      <address>
        <city>Uberlandia</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+553432913519</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Leon Richard Oncology Centre ( Site 0106)</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5068624030</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>William Osler Health System ( Site 0115)</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>9054942120</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program - London HSC ( Site 0107)</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5196858640</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lakeridge Health ( Site 0108)</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>9055768711</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIUSSS du Saguenay-Lac-St-Jean ( Site 0113)</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>4185411000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CISSS-CA Hotel Dieu de Levis ( Site 0111)</name>
      <address>
        <city>Lévis</city>
        <state>Quebec</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>4188357121</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St-Jerome Medical Research Inc ( Site 0103)</name>
      <address>
        <city>St-Jerome</city>
        <state>Quebec</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>450431102042</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre ( Site 0116)</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>3067662213</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre ( Site 0105)</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>3066552640</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional del Cancer ( Site 0912)</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana</state>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56984298842</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Regional de La Serena ( Site 0907)</name>
      <address>
        <city>La Serena</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56953360057</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Rancagua Libertador Bernardo O Higgins ( Site 0910)</name>
      <address>
        <city>Rancagua</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+569989022206</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Arturo Lopez Perez FALP ( Site 0902)</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56224457254</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Health and Care Chile ( Site 0901)</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56992214787</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universidad de Chile ( Site 0905)</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56998865341</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Militar de Santiago ( Site 0911)</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+569961918477</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Iram Cancer Research ( Site 0909)</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+569944332241</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pontificia Universidad Catolica de Chile ( Site 0904)</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56942477513</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Pablo Tobon Uribe. ( Site 0805)</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5744459753</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica de la Costa Ltda. ( Site 0804)</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5735336940</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancerologia ( Site 0807)</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5714320160</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncologos del Occidente S.A. ( Site 0800)</name>
      <address>
        <city>Pereira</city>
        <state>Risaralda</state>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5763310712</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion CardioInfantil Instituto de Cardiologia ( Site 0803)</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5716672727x73204</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncomedica S.A. ( Site 0801)</name>
      <address>
        <city>Monteria</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573135342052</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>FN Brno. ( Site 1501)</name>
      <address>
        <city>Brno</city>
        <zip>Prague 6</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420532233642</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nemocnice Novy Jicin a.s. Clen skupiny AGEL ( Site 1506)</name>
      <address>
        <city>Novy Jicin</city>
        <zip>Prague 6</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420724360436</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomouc ( Site 1502)</name>
      <address>
        <city>Olomouc</city>
        <zip>Prague 6</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420588444295</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Ostrava ( Site 1507)</name>
      <address>
        <city>Ostrava</city>
        <zip>Prague 6</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420721782888</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thomayerova nemocnice ( Site 1505)</name>
      <address>
        <city>Praha 4</city>
        <zip>Prague 6</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420261083530</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice v Motole ( Site 1504)</name>
      <address>
        <city>Praha 5</city>
        <zip>Prague 6</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420224434700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nemocnice Na Bulovce ( Site 1503)</name>
      <address>
        <city>Praha 8</city>
        <zip>Prague 6</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420266084516</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>HYKS ( Site 2300)</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+358504270943</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Keski-Suomen keskussairaala ( Site 2303)</name>
      <address>
        <city>Jyvaskyla</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+358142693586</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>TAYS ( Site 2301)</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+358331166535</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>TYKS ( Site 2302)</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+35823135925</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO Centre Paul Papin ( Site 2208)</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33241352734</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Besancon - Hopital Jean Minjoz ( Site 2200)</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33142116264</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Andre ( Site 2202)</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33556795708</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital La Timone ( Site 2204)</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33491385708</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Eloi ( Site 2203)</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33467332309</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou ( Site 2206)</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33156095833</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis ( Site 2209)</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33299253182</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Rene Gauducheau ICO ( Site 2207)</name>
      <address>
        <city>Saint Herblain</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33240679976</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud IUCT Oncopole ( Site 2201)</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33561424174</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Bonn ( Site 2110)</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4922828714428</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum der Technischen Universitaet Dresden ( Site 2113)</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+493514582442</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Dusseldorf ( Site 2108)</name>
      <address>
        <city>Dusseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+492118108776</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Erlangen. Waldkrankenhaus ( Site 2102)</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4991318223178</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen ( Site 2116)</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+492017232896</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Jena. ( Site 2104)</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+491711421827</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Schleswig Holstein ( Site 2109)</name>
      <address>
        <city>Luebeck</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+494515002290</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz ( Site 2111)</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+496131173608</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Studienpraxis Urologie ( Site 2115)</name>
      <address>
        <city>Nuertingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+491703809223</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brueder Trier ( Site 2117)</name>
      <address>
        <city>Trier</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+496512081921</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Tuebingen ( Site 2100)</name>
      <address>
        <city>Tuebingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4970712987235</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Ospedale San Donato ( Site 2004)</name>
      <address>
        <city>Arezzo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390575255439</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 2005)</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+393701279770</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia ( Site 2000)</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390257489460</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria di Modena Policlinico ( Site 2006)</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+393701279770</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 2003)</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390815903637</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Regina Elena ( Site 2009)</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390652666919</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nagoya University Hospital ( Site 0431)</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81527412111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sapporo Medical University Hospital ( Site 0424)</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81116112111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kagawa University Hospital ( Site 0419)</name>
      <address>
        <city>Kita-gun</city>
        <state>Kagawa</state>
        <zip>761-0793</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81878985111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Japan Community Health care Organization Sendai Hospital ( Site 0430)</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>981-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81222753111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nara Medical University Hospital ( Site 0416)</name>
      <address>
        <city>Kashihara</city>
        <state>Nara</state>
        <zip>634-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81744223051</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital ( Site 0411)</name>
      <address>
        <city>Osakasayama</city>
        <state>Osaka</state>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81723660221</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka Rosai Hospital ( Site 0418)</name>
      <address>
        <city>Sakai</city>
        <state>Osaka</state>
        <zip>591-8025</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81722523561</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saitama Medical University International Medical Center ( Site 0404)</name>
      <address>
        <city>Hidaka</city>
        <state>Saitama</state>
        <zip>350-1298</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81429844111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yamaguchi University Hospital ( Site 0406)</name>
      <address>
        <city>Ube</city>
        <state>Yamaguchi</state>
        <zip>755-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81836222111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akita University Hospital ( Site 0433)</name>
      <address>
        <city>Akita</city>
        <zip>010-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81188341111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harasanshin Hospital ( Site 0402)</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81922913434</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital ( Site 0413)</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81926411151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kumamoto University Hospital ( Site 0434)</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81963442111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nagano Municipal Hospital ( Site 0429)</name>
      <address>
        <city>Nagano</city>
        <zip>381-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81262951199</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Niigata University Medical &amp; Dental Hospital ( Site 0421)</name>
      <address>
        <city>Niigata</city>
        <zip>951-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81252236161</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka International Cancer Institute ( Site 0401)</name>
      <address>
        <city>Osaka</city>
        <zip>541-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81669451181</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital ( Site 0428)</name>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81666452121</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toranomon Hospital ( Site 0426)</name>
      <address>
        <city>Tokyo</city>
        <zip>105-8470</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81335881111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nippon Medical School Hospital ( Site 0400)</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8603</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81338222131</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital ( Site 0407)</name>
      <address>
        <city>Tokyo</city>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81333531211</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toyama University Hospital ( Site 0432)</name>
      <address>
        <city>Toyama</city>
        <zip>930-0194</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81764342281</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center ( Site 0300)</name>
      <address>
        <city>Seoul</city>
        <zip>4130</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82230105977</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center ( Site 0301)</name>
      <address>
        <city>Seoul</city>
        <zip>4130</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82234101767</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital ( Site 0302)</name>
      <address>
        <city>Seoul</city>
        <zip>4130</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>8222072721</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System ( Site 0303)</name>
      <address>
        <city>Seoul</city>
        <zip>4130</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82222288050</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mazowiecki Szpital Onkologiczny ( Site 1316)</name>
      <address>
        <city>Wieliszew</city>
        <state>Mazowieckie</state>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48227661500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Specjalistyczny w Koscierzynie Sp. z o.o. ( Site 1322)</name>
      <address>
        <city>Koscierzyna</city>
        <state>Pomorskie</state>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48586860413</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny ( Site 1309)</name>
      <address>
        <city>Brzozow</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48508233225</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny nr 4 w Bytomiu ( Site 1307)</name>
      <address>
        <city>Bytom</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48323964580</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojewodzkie Centrum Onkologii Copernicus ( Site 1304)</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48501372012</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Morski im. PCK Szpitale Wojewodzkie w Gdyni Sp. z o.o. ( Site 1302)</name>
      <address>
        <city>Gdynia</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48587260187</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Przychodnia Lekarska Komed ( Site 1306)</name>
      <address>
        <city>Konin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48632428009</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii Instytut im. Marii Sklodowskiej Curie ( Site 1310)</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48126348245</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii Ziemi Lubelskiej im. sw. Jana z Dukli ( Site 1315)</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Europejskie Centrum Zdrowia Otwock Szpital im. Fryderyka Chopina ( Site 1324)</name>
      <address>
        <city>Otwock</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48226817235</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny Przemienienia Panskiego UM im. K. Marcinkowskiego ( Site 1311)</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48601569568</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu ( Site 1305)</name>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48566101390</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Onkologii I Hipertermii ( Site 1321)</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48503320973</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojskowy Instytut Medyczny Centralny Szpital Medyczny MON ( Site 1300)</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48261817248</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ivanovo Regional Oncology Dispensary ( Site 1204)</name>
      <address>
        <city>Ivanovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79106672833</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>N.N. Blokhin NMRCO ( Site 1206)</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79037380779</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Medical Research Radiology Centre ( Site 1200)</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79646228228</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Russian Scientific Center of Roentgenoradiology ( Site 1201)</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79166590224</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Russian Scientific Center of Radiology and Surgical Technologies ( Site 1205)</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79219629807</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tomsk Scientific Research Institute of Oncology ( Site 1208)</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79039132574</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Bashkirsky Medical State University ( Site 1202)</name>
      <address>
        <city>Ufa</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79373573080</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Cristina ( Site 1805)</name>
      <address>
        <city>Badajoz</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3492421804048350</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau ( Site 1807)</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34932919000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Girona Dr. Josep Trueta ( Site 1806)</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34972225828</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Maranon ( Site 1801)</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34914269393</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal ( Site 1800)</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34913368263</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria ( Site 1808)</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34951032508</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra ( Site 1803)</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34948255400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncologia ( Site 1804)</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34961114605</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital. ( Site 0200)</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886422052121</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital ( Site 0202)</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>886223123456</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital ( Site 0201)</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>886228757519*303</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation. Linkou Branch ( Site 0203)</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>88633281200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Staffordshire Hospital in Stoke-on-Trent ( Site 1601)</name>
      <address>
        <city>Stoke-On-Trent</city>
        <state>Staffordshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441782672599</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Western General Hospital ( Site 1600)</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441315372211</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Beatson West of Scotland Cancer Centre ( Site 1605)</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441413017064</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charing Cross Hospital ( Site 1607)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442033117627</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital ( Site 1609)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442078828505</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St George's Healthcare Trust ( Site 1608)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442087523829</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust ( Site 1602)</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441614463000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The James Cook University Hospital ( Site 1606)</name>
      <address>
        <city>Middlesbrough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441642854353</phone>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2017</study_first_submitted>
  <study_first_submitted_qc>May 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2017</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PD1</keyword>
  <keyword>PD-1</keyword>
  <keyword>PDL1</keyword>
  <keyword>PD-L1</keyword>
  <keyword>Adjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

